软性自膨式金属支架治疗慢性胰腺炎继发疼痛性胰管狭窄:一项前瞻性多中心试验
这项前瞻性多中心单臂试验评估了研究用软性胰腺全覆膜自膨式金属支架(FCSEMS)治疗慢性胰腺炎相关疼痛的疗效与安全性。67例患者中技术成功率为97.0%(65/67),主要疗效终点(26.1%,12/46)和安全性终点(31.3%,21/67)均未达到预设研究假设,支架移位发生率为47.7%(31/65)。
要点
- 6个月FCSEMS治疗未达到预期疼痛缓解程度,主要疗效终点26.1%(12/46)未达预设目标≥53%。
- 支架相关严重不良事件发生率为31.3%(21/67),未达预设安全性目标<32%。
- 支架移位发生率为47.7%(31/65),研究结论认为需进一步研究优化减压策略、支架设计和患者选择。
核心结论
- 6个月FCSEMS治疗未带来预期程度的疼痛缓解,支架移位和严重不良事件常见。
- 需进一步研究以明确最佳减压策略、FCSEMS设计和患者选择。
研究设计与样本
- 前瞻性、多中心、单臂试验,研究6个月留置4至6厘米长软性胰腺FCSEMS。
- 纳入67例疼痛性慢性胰腺炎、主导性远端胰管狭窄且上游胰管扩张的患者,平均年龄52.7±12.5岁,自慢性胰腺炎诊断以来平均时间6.4±6.4年。
- 主要疗效终点在放置FCSEMS时疼痛足够严重且频繁、作为首次支架或交换塑料支架的患者中评估,共46例符合分析条件。
- 主要疗效终点为FCSEMS留置6个月后疼痛减轻(性能目标≥53%),主要安全性终点为胰管支架置入相关严重不良事件(性能目标<32%)。
主要发现
- 技术成功率为97.0%(65/67)。
- 主要疗效终点观察值为26.1%(12/46),未达到预设研究假设。
- 主要安全性终点观察值为31.3%(21/67),未达到预设研究假设。
- 研究支架移位发生于47.7%的患者(31/65)。
- 34例(50.7%)在放置FCSEMS前90天内放置过塑料支架。
关键数值与推荐
- 主要疗效终点性能目标≥53%,观察值26.1%(12/46)未达到。
- 主要安全性终点性能目标<32%,观察值31.3%(21/67)未达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究以明确最佳减压策略、FCSEMS设计和患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Fully covered self-expandable metal stents (FCSEMSs) may offer a treatment option for pain associated with a dilated pancreatic duct (PD) in chronic pancreatitis (CP), but optimal patient selection and FCSEMS design, efficacy, and safety remain uncertain. We studied an investigational pancreatic FCSEMS for treatment of CP-associated pain. METHODS: Patients with painful CP, a dominant distal PD stricture, and PD dilation upstream were enrolled in a prospective, multicenter, single-arm trial studying 6-month indwell of a 4- to 6-cm-long soft pancreatic FCSEMS. Primary efficacy and safety endpoints were pain reduction 6 months after FCSEMS indwell (performance goal ≥53%) and PD stenting-related serious adverse events (SAEs), respectively (performance goal <32%). The primary efficacy endpoint was assessed in patients with sufficiently severe and frequent pain at FCSEMS placement as a first stent or in exchange of a plastic stent. RESULTS: Among 67 patients (mean age, 52.7 ± 12.5 years; mean time since CP diagnosis, 6.4 ± 6.4 years), 34 (50.7%) had plastic stent placement within 90 days of FCSEMS placement, and 46 patients were eligible for the primary efficacy endpoint analysis. Technical success was 97.0% (65/67). The observed primary efficacy (26.1%, 12/46) and safety endpoints (31.3%, 21/67) failed to meet the a priori study hypotheses. Study stent migration occurred in 47.7% of patients (31/65). CONCLUSIONS: Six-month treatment with an FCSEMS did not lead to an expected degree of pain reduction, and migrations and SAEs were common. Further study is needed to clarify optimal decompressive strategy, FCSEMS design, and patient selection. (Clinical trial registration number: NCT02802020.).
引用
- Sherman S, Kozarek RA, Costamagna G, et al. Soft self-expandable metal stent to treat painful pancreatic duct strictures secondary to chronic pancreatitis: a prospective multicenter trial. Gastrointest Endosc. 2022. PMID: 36208796. doi:10.1016/j.gie.2022.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。